Avidity Partners 13F holdings, Q4 2019
Holdings as of December 31, 2019 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 33 US equity positions worth $158.7m in its Q4 2019 13F filing. The largest position was BAX at 8.7% of the reported book, followed by HCA and VRTX.
What did Avidity Partners own in Q4 2019? Top 33 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | BAX BAXTER INTL INC | Healthcare | 8.7% | $13.8m | 165,000 | – | |
| 2 | HCA HCA HEALTHCARE INC | Healthcare | 5.8% | $9.3m | 62,700 | – | |
| 3 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 5.5% | $8.8m | 40,000 | – | |
| 4 | ABBV ABBVIE INC | Healthcare | 5.2% | $8.3m | 94,000 | – | |
| 5 | MIRATI THERAPEUTICS INC | 5.2% | $8.2m | 64,000 | – | ||
| 6 | ZBH ZIMMER BIOMET HLDGS INC | Healthcare | 5.1% | $8.2m | 54,500 | – | |
| 7 | ESPERION THERAPEUTICS INC NE | 4.9% | $7.8m | 130,400 | – | ||
| 8 | EW EDWARDS LIFESCIENCES CORP | Healthcare | 4.0% | $6.3m | 27,000 | – | |
| 9 | CI CIGNA CORP NEW | Healthcare | 3.9% | $6.1m | 30,000 | – | |
| 10 | ASND ASCENDIS PHARMA A S | Healthcare | 3.7% | $5.9m | 42,100 | – | |
| 11 | AXNX* AXONICS MODULATION TECH INC | 3.6% | $5.8m | 208,000 | – | ||
| 12 | HORIZON THERAPEUTICS PUB LTD | 3.4% | $5.4m | 150,000 | – | ||
| 13 | NXTC NEXTCURE INC | 3.3% | $5.2m | 93,000 | – | ||
| 14 | CATALENT INC | 3.3% | $5.2m | 92,000 | – | ||
| 15 | AUPH AURINIA PHARMACEUTICALS INC | Healthcare | 3.0% | $4.7m | 232,000 | – | |
| 16 | DVAX DYNAVAX TECHNOLOGIES CORP | 2.8% | $4.5m | 780,000 | – | ||
| 17 | ABEO ABEONA THERAPEUTICS INC | 2.7% | $4.3m | 1,325,000 | – | ||
| 18 | DXCM DEXCOM INC | Healthcare | 2.6% | $4.2m | 19,000 | – | |
| 19 | MNTA MOMENTA PHARMACEUTICALS INC | 2.5% | $3.9m | 200,000 | – | ||
| 20 | UNIQURE NV | 2.5% | $3.9m | 55,000 | – | ||
| 21 | CHRS COHERUS BIOSCIENCES INC | Healthcare | 2.4% | $3.9m | 214,500 | – | |
| 22 | KDMN KADMON HLDGS INC | 2.4% | $3.8m | 830,000 | – | ||
| 23 | COLL COLLEGIUM PHARMACEUTICAL INC | Healthcare | 2.3% | $3.7m | 180,000 | – | |
| 24 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.2% | $3.5m | 33,000 | – | |
| 25 | IMMU IMMUNOMEDICS INC | 1.9% | $3.0m | 140,000 | – | ||
| 26 | EXK EXACT SCIENCES CORP | Basic Materials | 1.8% | $2.9m | 31,000 | – | |
| 27 | NEOLEUKIN THERAPEUTICS INC | 1.6% | $2.6m | 210,000 | – | ||
| 28 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 1.5% | $2.3m | 54,000 | – | |
| 29 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 0.9% | $1.4m | 15,000 | – | |
| 30 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.4% | $683.0k | 30,000 | – | |
| 31 | SUNESIS PHARMACEUTICALS INC | 0.3% | $473.0k | 1,400,000 | – | ||
| 32 | ARAVIVE INC | 0.3% | $410.0k | 30,000 | – | ||
| 33 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.2% | $390.0k | 10,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.